CROI 2025 will cover viral infections, treatments, and potential cures, focusing on HIV, COVID-19, STIs, and hepatitis C. The conference will feature plenary sessions on HIV research, global ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) delivered a late-breaking scientific oral ...

On Wednesday, Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). ALLIANCE is ...

Top content from CROI 2025 focused on COVID-19 and HIV, including the safety of a vaccine in people taking antiretroviral therapy. Our top content coverage from the Conference on Retroviruses and ...

Findings in HIV highlight AMV technology's versatility, robust immune response, and excellent safety profile, underpinning company's expansion into oncology applications Paris, France – March 13, 2025 ...

Immunocore reports positive initial data for HIV treatment candidate IMC-M113V, showing safety and signs of viral control post-treatment. The observation of delayed viral rebound and/or viremia ...

The data were presented during an oral abstract session at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) and were also published today in The Lancet. Data will support the ...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 10 March 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company ...

Findings in HIV highlight AMV technology's versatility, robust immune response, and excellent safety profile, underpinning company’s expansion into oncology applications AMVs are a new class of ...